InvivoCrown In vivo TNFα neutr

InVivoPro Anti-Mouse CTLA-4 (CD152) in vivo antibody, Clone 9D9InVivoPro Anti-Mouse TNFα in vivo antibody, Clone TN3-19.12Mouse IgG2bArmenian Hamster IgG9D9TN3-19.12CTLA-4TNFαCD152, Cytotoxic T Lymphocyte-Associated Antigen-4, Ly-56TNF-alpha, TNFSF2, Tnlg1fMouse IgG2b Isotype ControlArmenian Hamster IgG Isotype ControlPBS, pH 7.2, contains no stabilizers or preservativesPBS, pH 7.2, contains no stabilizers or preservativesMouseMouseMouseArmenian Hamster200-500 μg per mouse; or 10-20 mg/kg. This range is based off the most recent publication data using the 9D9 clone in vivo. Each investigator should determine their own optimal working dilution for specific applications.200-500 μg per mouse; or 10-20 mg/kg. This range is based off the most recent publication data using the TN3-19.12 clone in vivo. Each investigator should determine their own optimal working dilution for specific applications.15212Sade-Feldman, Moshe et al. "Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma",Cell 175.4 (2018): 998-1013.e20. Benci, Joseph L. et al. "Opposing Functions of Interferon Coordinate Adaptive and Innate Immune Responses to Cancer Immune Checkpoint Blockade",Cell 178.4 (2019): 933-948.e14. Cappellesso, Federica et al. "Targeting the Bicarbonate Transporter SLC4A4 Overcomes Immunosuppression and Immunotherapy Resistance in Pancreatic Cancer",Nature cancer 3.12 (2022): 1464-1483.Dudek, Michael et al. "Auto-aggressive CXCR6+ CD8 T Cells Cause Liver Immune Pathology in NASH",Nature (2022) Gulen, Muhammet F. et al. "Cgas–sting Drives Ageing-Related Inflammation and Neurodegeneration",Nature 620.7973 (2023): 374-380. Ma, Leyuan et al. "Vaccine-boosted CAR T Crosstalk with Host Immunity to Reject Tumors with Antigen Heterogeneity",Cell (2023)CTLA-4 is a 33 kD member of the Ig superfamily similar to CD28 in amino acid sequence, structure, and genomic organization. CTLA-4 is a protein receptor that functions as an immune checkpoint and downregulates immune responses. It is involved in the development of protective immunity and thymocyte regulation, in addition to the induction and maintenance of immunological tolerance. CTLA-4 has therapeutic potential both as an agonist to reduce immune activity, and an antagonist to increase immune activity.The tumor necrosis factor (TNF-alpha) is a multifaceted polypeptide cytokine known as a mediator of inflammation and immunity. It may mediate some of the significant changes in cellular homeostasis which accompany the invasion of the mammalian host by viruses, bacteria, and parasites. TNF-alpha is an acute phase protein which initiates a cascade of cytokines and increases vascular permeability, thereby recruiting macrophage and neutrophils to a site of infection. TNF-alpha secreted by the macrophage causes blood clotting which serves to contain the infection. TNF-alpha has been detected in synovial fluid of patients with rheumatoid arthritis. Clone TN3-19.12 antibody can neutralize the bioactivity of natural or recombinant TNF-alpha.In vivo CTLA-4 neutralization, Western blotIn vivo TNFα neutralization, Enzyme-linked Immunosorbent Assayprotein A or Gprotein A or GThis antibody is stable for at least 2 months when stored at 2-8°C. For long term storage, aliquot in working volumes without diluting and store at -20°C or -80°C. Avoid repeated freeze thaw cycles.This antibody is stable for at least 2 months when stored at 2-8°C. For long term storage, aliquot in working volumes without diluting and store at -20°C or -80°C. Avoid repeated freeze thaw cycles.2-8°C with blue ice2-8°C with blue iceLot specific, generally ≥ 5.0 mg/mlLot specific, generally ≥ 5.0 mg/ml12 months from the date of receipt if stored as recommended12 months from the date of receipt if stored as recommendedPBS Buffer, PH 7.2, with no carrier protein, or preservatives.PBS Buffer, PH 7.2, with no carrier protein, or preservatives.0.2 μM filtered0.2 μM filtered≤ 1.0 EU/mg, by the LAL method≤ 1.0 EU/mg, by the LAL method0.990.99可替换BioXCell产品货号为BE0058